- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02049840
The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence (EASY)
September 23, 2021 updated by: Coloplast A/S
This is a prospective, post-market, single arm, multicenter study comparing Baseline data to the 12 month and 36 month data in 136 female patients with Stress Urinary Incontinence
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, European Post-Market, one non-controlled arm, multi-centre clinical trial conducted at up to 10 centers in Europe.
It is designed to get more clinical information for users (uro-gynecologists) of the Altis Single Incision Sling System for female stress urinary incontinence treatment in terms of objective and subjective cure rate, quality of life improvement, patient satisfaction and safety, especially in long term follow-up (3 years).
Clinical data will be collected at baseline, implantation procedure, post-operative at 6 weeks, 6 months, 1, 2 and 3 years
Study Type
Interventional
Enrollment (Actual)
153
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bron, France, 69677
- Hôpital Femme Mère Enfant
-
Marseille, France, 13005
- Hôpital de la Conception
-
Nîmes, France, 30029
- Centre Hospitalier Universitaire Carémeau - Gyneacology
-
Nîmes, France, 30029
- Centre Hospitalier Universitaire Caremeau
-
Rouen, France, 76031
- Centre Hospitalier Universitaire de Rouen - Hôpital Charles Nicolle
-
Strasbourg, France, 67091
- Nouvel Hôpital Civil
-
-
-
-
-
München, Germany, 80331
- Isarklinikum
-
München, Germany, 81679
- Chirurgische Klinik München - Bogenhausen GmbH
-
-
-
-
-
Catania, Italy, 95122
- Ospedale Garibaldi-Nesima
-
-
-
-
-
Zwolle, Netherlands, 8025
- ISALA Klinieken Locatie Sophia
-
-
-
-
-
Madrid, Spain, 28040
- Fundación Jiménez Díaz
-
-
Valencia
-
Alcira, Valencia, Spain, 46600
- Hospital Universitario La Ribera
-
Sagunto, Valencia, Spain, 46520
- Hospital de Sagunto
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- The subject is female at least 18 years of age
- The subject uses a method of contraception considered effective by the investigator or is not of child-bearing potential
- The subject is able and willing to complete all procedures and follow-up visits indicated in this protocol.
- The subject has confirmed stress urinary incontinence (SUI) through cough stress test at baseline.
- The subject has failed first line treatments (non-invasive therapies, eg. behavioral modification, Pelvic Floor/Kegel exercises, or biofeedback) with good compliance for the treatment
Exclusion Criteria:
- The subject had a prior surgical SUI treatment (including bulking agent).
- The subject is having a concomitant Pelvic Organ Prolapse repair or hysterectomy during Altis procedure.
- The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions).
- The subject has predominant or uncontrolled or primary urge incontinence according to investigator judgment
- The patient has detrusor overactivity determined through urodynamics
- The subject has intrinsic sphincter deficiency defined urodynamically as a Maximal Urethral Closure Pressure < 20 cm H2O and/or Valsalva Leak Point Pressure < 60 cm H2O
- The subject has atonic bladder, a persistent post void residual (PVR) > 100 ml or chronic urinary retention.
- The subject has untreated urinary malignancy
- The subject has undergone radiation or brachy therapy or chemotherapy to treat pelvic cancer.
- The subject has urethrovaginal fistula or urethral diverticulum or congenital urinary anomalies
- The subject has serious bleeding disorder or requires anticoagulant therapy
- The subject is pregnant and/or is planning to get pregnant in the future.
- The subject has a Body Mass Index ≥ 35 (obese class II).
- The subject has a contraindication to the surgical procedure according to the the Altis SIS System IFU.
- The subject has an active urogenital infection or active skin infection in region of surgery mainly at the time of implantation.
- The subject is enrolled in a concomitant clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Altis Single Incision Sling System
|
Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects who meet the criteria of cure at 12 months
Time Frame: 1 year
|
Cure is defined as negative Cough Stress Test (CST) and an answer "no" to question 3 "Do you usually experience urine leakage related to coughing, sneezing, or laughing?" of the UDI-6 questionnaire
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects who have a negative cough stress test at each visit
Time Frame: 6 weeks, 6 months, 1 year, 2 year, 3 year
|
6 weeks, 6 months, 1 year, 2 year, 3 year
|
|
Proportion of subjects who meet the criteria of cure at each other visit
Time Frame: 6 weeks, 6 months, 2 year, 3 year
|
Cure is defined as negative Cough Stress Test (CST) and an answer "no" to question 3 "Do you usually experience urine leakage related to coughing, sneezing, or laughing?" of the UDI-6 questionnaire
|
6 weeks, 6 months, 2 year, 3 year
|
Subject continence status measured by the 24-hour pad weight
Time Frame: 6 weeks, 1 year
|
The continence status will be described : Proportion of subjects who meet the criteria of dryness defined as a pad weight of less than 8 grams for the current practice Proportion of subjects who meet the criteria of improvement defined as at least a 50% reduction in pad weight from baseline
|
6 weeks, 1 year
|
Assessment of self reported symptoms and subject QoL through the scoring of validated questionnaires: ICIQ-UI SF, I-QOL, UDI-6 and IIQ-7
Time Frame: 6 weeks, 6 months, 1 year, 2 year, 3 year
|
The scores of ICIQ-UI short form, I-QOL, UDI-6 and IIQ-7 will be describe at each visit as continuous variables.
The evolution of scores from baseline will be presented
|
6 weeks, 6 months, 1 year, 2 year, 3 year
|
Postoperatively subject impression of improvement (via PGI-I questionnaire) and satisfaction at each post-operative visit
Time Frame: 6 weeks, 6 months, 1 year, 2 year, 3 year
|
6 weeks, 6 months, 1 year, 2 year, 3 year
|
|
Assessment of Qmax variations
Time Frame: 6 weeks, 1year
|
Qmax (maximum flow rate in uroflowmetry section) raw value (at baseline, 6 weeks and 12 months) and absolute and relative variations from baseline et 6 weeks and 12 months will be described
|
6 weeks, 1year
|
Assessment of PVR variations
Time Frame: 6 weeks, 1 year
|
PVR (Post void residual urine volume) raw value (at baseline, 6 weeks and 12 months) and absolute and relative variations from baseline et 6 weeks and 12 months will be described
|
6 weeks, 1 year
|
Assessment of the operation duration and the type of anaesthesia used
Time Frame: Operative period
|
Operative period
|
|
Assessment of device and procedure related adverse events
Time Frame: Operative period, 6 weeks, 6 months, 1 year, 2 year, 3 year
|
All device or procedure related Adverse Events (AE) will be summarized and reported as the number and percentage of subjects having this AE and as the number and percentage of AE in Safety population.
|
Operative period, 6 weeks, 6 months, 1 year, 2 year, 3 year
|
Assessment of postoperative pain
Time Frame: operative period, 6 weeks, 6 months, 1 year
|
Visual Analogue Scale from 0 "no pain" to 10 "extreme pain"
|
operative period, 6 weeks, 6 months, 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jean-Nicolas Cornu, Pr, Centre Hospitalier Universitaire de Rouen - Hôpital Charles Nicolle
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 16, 2013
Primary Completion (Actual)
November 4, 2019
Study Completion (Actual)
July 21, 2021
Study Registration Dates
First Submitted
January 28, 2014
First Submitted That Met QC Criteria
January 28, 2014
First Posted (Estimate)
January 30, 2014
Study Record Updates
Last Update Posted (Actual)
September 28, 2021
Last Update Submitted That Met QC Criteria
September 23, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SU016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress Urinary Incontinence
-
University of New MexicoRecruitingUrinary Incontinence | Urge Incontinence | Stress Incontinence, FemaleUnited States
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Stanford...CompletedUrinary Incontinence, Stress | Urge Incontinence | Urinary Stress Incontinence | Stress Incontinence, Urinary | Stress Incontinence | Stress Incontinence, Female | Urgency UrinaryUnited States
-
Juna d.o.o.CompletedFemale Stress Urinary Incontinence | Mixed Incontinence, Urge and Stress
-
Far Eastern Memorial HospitalRecruitingWomen With Stress Urinary IncontinenceTaiwan
-
Université de SherbrookeRecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, MaleCanada
-
Hadassah Medical OrganizationCompletedUrinary Stress Incontinence (SI)Israel
-
University Magna GraeciaUnknownStress Urinary IncontinenceItaly
-
University of California, IrvineWithdrawnStress Urinary IncontinenceUnited States
-
Eli Lilly and CompanyBoehringer IngelheimCompleted
-
Eli Lilly and CompanyBoehringer IngelheimCompletedUrinary Stress IncontinenceUnited States
Clinical Trials on Altis Single Incision Sling System
-
Coloplast A/SActive, not recruitingUrinary Incontinence, StressSpain, Belgium, France, Germany, Italy
-
Coloplast A/SCompletedStress Urinary IncontinenceUnited States, Canada
-
Coloplast A/SCompletedStress Urinary IncontinenceUnited States, Canada
-
Michigan Institution of Women's Health PCActive, not recruitingStress Urinary IncontinenceUnited States
-
Boston Scientific CorporationCompletedStress Urinary IncontinenceUnited States, Australia
-
Maltepe UniversityCompletedStress Urinary IncontinenceTurkey
-
C. R. BardCompletedFemale Stress Urinary IncontinenceUnited States
-
American Medical SystemsUnknownStress Urinary Incontinence in WomenUnited States
-
The Christ HospitalCompletedStress Incontinence, FemaleUnited States